This was a randomized, double-blind, placebo-controlled parallel study.
Not Provided
Drug: Jaktinib
100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with
best available treatment.
Drug: Placebo
Placebo (given as two placebo tablets) administered orally BID with best available
treatment.
Inclusion Criteria:
- 18 years of age, male or female;
- History of COVID-19 infection within 1 week;
- Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and
meeting any of the following criteria: With fever, respiratory symptoms; Shortness
of breath present,RR ≥30 breaths/min.
- Clear consciousness, Capable and voluntary informed consent.
Exclusion Criteria:
- Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of
the same class, or their excipients, Patients with severe gastrointestinal
dysfunction affecting drug absorption;
- Any person meeting criteria for critical pneumonia;
- Patients considered unsuitable for this trial by the investigator.
The First Affiliated Hospital of College of Medicine Zhejiang University
Hangzhou, Zhejiang, China
Investigator: Jianya Zhou
Jianya Zhou
0571-87235114
zhoujianya@hotmail.com
Jianya Zhou, Principal Investigator
First Affiliated Hospital of Zhejiang University